Hollis-Edent (HEPH) is a very small development-stage pharmaceutical company. It has no revenue as has lost about $7 million each of the last couple of years.
The stock has been a world class dog falling from a 52-week high of $7.49 to $1.42. But, some of that changed today. The shares are up 30% to $2.16 on news that "data from an animal study showed its cancer drug candidate, HE3235, continued to prevent breast cancer tumor growth even after dosing ended," according to Reuters. "The lasting anti-tumor effect of HE3235 reported in this animal model of breast cancer suggests the compound is causing tumor cells to undergo apoptosis, or die," said Richard B. Hollis, chairman and CEO of Hollis-Eden.
Is the company worth its current $153 million market cap? No way to tell. The development of the treatment is still early and there is no revenue attached to it.
Crap shoot.
Douglas A. McIntyre
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.